Related Experiment Video
Updated: Aug 20, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.8K
TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Stefan Barth1,2, Krupa Naran1
1Medical Biotechnology and Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Immunotherapy Advances
|November 21, 2022
Summary
Sabatolimab, an anti-TIM-3 antibody, offers a novel approach to cancer immunotherapy by targeting TIM-3 receptors on immune and myeloid cells. This investigational therapy shows promise for treating myeloproliferative disorders like acute myeloid leukemia.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint inhibitors represent a significant advancement in cancer immunotherapy.
- TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is a receptor expressed on immune effector and myeloid cells, implicated in immune regulation.
- Myeloproliferative disorders, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), represent a critical area for novel therapeutic strategies.
Purpose of the Study:
- To introduce sabatolimab, a humanized anti-TIM-3 monoclonal antibody.
- To elucidate the distinct mechanisms of action of sabatolimab beyond canonical immune checkpoint inhibition.
- To highlight the potential of sabatolimab in treating myeloproliferative disorders.
Main Methods:
- Development of a high-affinity, humanized monoclonal antibody targeting TIM-3.
- Investigation of sabatolimab's effects on TIM-3 receptor and its ligands (PtdSer/galectin-9).
- Assessment of sabatolimab's impact on leukemic cell self-renewal and antibody-dependent phagocytosis.
Main Results:
- Sabatolimab targets TIM-3, a receptor on immune and myeloid cells.
- Mechanisms include blockade of TIM-3/ligand interactions, modulation of leukemic cell self-renewal, and antibody-dependent phagocytosis.
- These actions enhance the antitumor immune response through multiple pathways.
Conclusions:
- Sabatolimab represents a novel immunotherapeutic agent for myeloproliferative disorders.
- Its multi-pronged mechanism of action offers a distinct approach compared to existing immunotherapies.
- Sabatolimab holds promise as a future treatment option for hematologic malignancies.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
631
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
631
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K